Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Niacinamide

FDA-approved product (injectable, injection).

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Niacinamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acne
  • Anemia (phenotype)
  • Folate deficiency
  • Iron deficiency anemia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other plain vitamin preparations
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Niacinamide, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA5.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli20.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae3.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis11.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Niacinamide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-4.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-5.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Niacinamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder

    NCT01222676 · start 2010-10

    Registered record
    Registry ID
    NCT01222676
    Conditions
    Bladder Cancer
    Interventions
    cisplatin; gemcitabine hydrochloride; sorafenib tosylate; imaging biomarker analysis; laboratory biomarker analysis; computed tomography; neoadjuvant therapy; fludeoxyglucose F 18
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2010-10
    Completion
    Not recorded
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBladder Cancer
    Interventioncisplatin; gemcitabine hydrochloride; sorafenib tosylate; imaging biomarker analysis +4 more
    PhasePhase 2
    Registry statusUnknown

  • Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease

    NCT01147042 · start 2010-05-18

    Registered record
    Registry ID
    NCT01147042
    Conditions
    IFN-Gamma Therapy; CGD Gene Mutation; CGD Response to IFNg; CGD - Chronic Granulomatous Disease; Immunodeficiency Disease
    Interventions
    IFN-gamma
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2010-05-18
    Completion
    2014-11-14
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIFN-Gamma Therapy; CGD Gene Mutation; CGD Response to IFNg; CGD - Chronic Granulomatous Disease +1 more
    InterventionIFN-gamma
    PhasePhase 4
    Registry statusTerminated

  • Clinical Study to Test a New Drug to Treat Major Depression

    NCT00976560 · start 2009-09-25

    Registered record
    Registry ID
    NCT00976560
    Conditions
    Depressive Disorder, Major
    Interventions
    GW856553; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-09-25
    Completion
    2010-07-07
    Enrolment
    128

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepressive Disorder, Major
    InterventionGW856553; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Study to Test GSK256073 in Patients With Dyslipidemia

    NCT00903617 · start 2009-06-15

    Registered record
    Registry ID
    NCT00903617
    Conditions
    Dyslipidaemias; Dyslipidemias
    Interventions
    GSK256073; GSK256073; GSK256073; Placebo; Niaspan; GSK256073; GSK256073
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-06-15
    Completion
    2010-02-16
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDyslipidaemias; Dyslipidemias
    InterventionGSK256073; GSK256073; GSK256073; Placebo +3 more
    PhasePhase 2
    Registry statusCompleted

  • Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer

    NCT00867321 · start 2009-04

    Registered record
    Registry ID
    NCT00867321
    Conditions
    Liver Cancer
    Interventions
    bevacizumab; sorafenib tosylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2009-04
    Completion
    2013-05
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Cancer
    Interventionbevacizumab; sorafenib tosylate
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Comparison of Fenofibrate and Niacin in Patients With Hypertriglyceridemia and Low High-Density Lipoprotein (HDL)-Cholesterol

    NCT01122355 · start 2009-02

    Registered record
    Registry ID
    NCT01122355
    Conditions
    Hypertriglyceridemia With Low HDL-cholesterol
    Interventions
    lipid modification
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-02
    Completion
    2010-01
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertriglyceridemia With Low HDL-cholesterol
    Interventionlipid modification
    PhasePhase 4
    Registry statusCompleted

  • Tolerance and Efficacy of Formulation 609580 20 Versus Formulation 609209 in Children With Atopic Dermatitis

    NCT00931411 · start 2009-01

    Registered record
    Registry ID
    NCT00931411
    Conditions
    Atopic Dermatitis
    Interventions
    Formulation 609580 20; Formulation 609209 (Lipikar Baume)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2009-01
    Completion
    2009-07
    Enrolment
    73

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionFormulation 609580 20; Formulation 609209 (Lipikar Baume)
    PhaseNot applicable
    Registry statusTerminated

  • Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

    NCT00687674 · start 2008-08

    Registered record
    Registry ID
    NCT00687674
    Conditions
    Multiple Myeloma and Plasma Cell Neoplasm
    Interventions
    dexamethasone; sorafenib tosylate; Lenalidomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2008-08
    Completion
    2011-11
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma and Plasma Cell Neoplasm
    Interventiondexamethasone; sorafenib tosylate; Lenalidomide
    PhasePhase 1
    Registry statusTerminated

  • Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.

    NCT00622479 · start 2008-05

    Registered record
    Registry ID
    NCT00622479
    Conditions
    Carcinoma, Renal Cell
    Interventions
    Sorafenib (Nexavar, BAY43-9006)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2008-05
    Completion
    2010-11
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Renal Cell
    InterventionSorafenib (Nexavar, BAY43-9006)
    PhasePhase 1
    Registry statusTerminated

  • Study of Niacin on Endothelial Function in HIV-infected Subjects With Low High Density Lipoprotein Cholesterol Levels

    NCT00986986 · start 2007-11

    Registered record
    Registry ID
    NCT00986986
    Conditions
    HIV Infections; Dyslipidemia; Endothelial Dysfunction
    Interventions
    extended release niacin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2007-11
    Completion
    2010-04
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Dyslipidemia; Endothelial Dysfunction
    Interventionextended release niacin
    PhaseNot applicable
    Registry statusCompleted

  • The Genetics of Evoked Responses to Niacin and Endotoxemia: The GENE Study

    NCT00953667 · start 2007-06

    Registered record
    Registry ID
    NCT00953667
    Conditions
    Healthy Volunteers
    Interventions
    Immediate Release Niacin, Extended Release Niacin, Endotoxin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2007-06
    Completion
    2011-02
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionImmediate Release Niacin, Extended Release Niacin, Endotoxin
    PhaseNot applicable
    Registry statusCompleted

  • Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma

    NCT00538005 · start 2007-05

    Registered record
    Registry ID
    NCT00538005
    Conditions
    Melanoma (Skin)
    Interventions
    bevacizumab; oxaliplatin; sorafenib tosylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2007-05
    Completion
    Not recorded
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma (Skin)
    Interventionbevacizumab; oxaliplatin; sorafenib tosylate
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • A Trial of Vitamins and HAART in HIV Disease Progression

    NCT00383669 · start 2006-11

    Registered record
    Registry ID
    NCT00383669
    Conditions
    HIV Infections
    Interventions
    Multivitamins (including B, C and E); Multivitamins B, C and E
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-11
    Completion
    2009-10
    Enrolment
    4,012

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionMultivitamins (including B, C and E); Multivitamins B, C and E
    PhasePhase 3
    Registry statusCompleted

  • Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

    NCT00335764 · start 2006-04

    Registered record
    Registry ID
    NCT00335764
    Conditions
    Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor
    Interventions
    sorafenib tosylate; erlotinib hydrochloride; tipifarnib; temsirolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2006-04
    Completion
    2012-09
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor
    Interventionsorafenib tosylate; erlotinib hydrochloride; tipifarnib; temsirolimus
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma

    NCT00253578 · start 2006-03

    Registered record
    Registry ID
    NCT00253578
    Conditions
    Refractory Multiple Myeloma
    Interventions
    sorafenib tosylate; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-03
    Completion
    Not recorded
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRefractory Multiple Myeloma
    Interventionsorafenib tosylate; laboratory biomarker analysis
    PhasePhase 2
    Registry statusCompleted